Cue Health has announced plans to develop an Omicron-Genotyping Covid-19 test in partnership with the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services.
The company stated that the test will complement its existing molecular Covid-19 test, which has the capability to identify all known variants of the disease, including the Omicron variant.
The new test will be used in professional point-of-care settings to specifically detect the Omicron variant in nasal samples.
It will be designed to be compatible with the Cue Health Mobile Application and Cue Health Monitoring System.
The new Covid-19 test will provide the latest health information to clinicians and researchers in order to support informed treatment as well as real-time containment decisions.
Cue Health plans to utilise the additional funding obtained from BARDA to speed up the test’s development, validation and regulatory authorisation process.
Cue Health co-founder and CEO Ayub Khattak said: “An Omicron-specific test will assist clinicians in providing patients better treatment options and containment strategies at the time of a positive diagnosis.
“We are proud to partner with BARDA to develop this new test, which will help eliminate guesswork, provide more choices for patients and strengthen public health outcomes for communities.”
Since 2018, the company has been working with BARDA, receiving $30m in base funding.
BARDA awarded $13m to Cue Health in March 2020 to fast-track the development, validation and Food and Drug Administration (FDA) clearance of a molecular diagnostic test.
Last month, Cue Health received authorisation from the Health Sciences Authority (HSA) in Singapore for its molecular Covid-19 test for self-testing.